 The purpose of this research study is to assess the response rate of LBH589 in patients with relapsed or refractory Waldenstroms Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstroms Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma. 